Science 37 and BEKHealth Collaborate to Expand Patient Access Via Community Providers
November 22 2022 - 10:47AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading
Metasite™, and BEKHealth, a leading clinical research platform,
today announced a partnership that will enable Science 37 to access
the EMR data, exclusively, across its network of more than 35
thousand community providers, covering more than 35 million patient
lives–expanding participant access, accelerating enrollment, and
potentially reducing time to market for important investigational
treatments and therapies.
“As a virtual site, Science 37 is in the unique position to be
able to access patients that are unavailable through a traditional
site network,” said Darcy Forman, Chief Delivery Officer at Science
37. “Directly accessing the EMR data across our community providers
enables us to get much more precise at feasibility and to
accelerate enrollment through one of our most prolific patient
recruitment channels.”
Today, less than 3% of all providers are clinical research
investigators. Given their limited access to patients, less than 8%
of patients are ever contacted to participate in clinical research.
By using BEKHealth’s A.I. technology to search the electronic
medical records of patients within Science 37’s extensive community
provider network, Science 37 can match individual patients to
specific clinical trial cohorts. This expands access to include
patients who weren’t previously able to participate, increasing
both the volume of participants and the speed of enrollment.
“We are delighted to work with Science 37 to expand access to
clinical trials, particularly within under-represented
communities,” said Jason Baumgartner, President and CEO at
BEKHealth. “By applying our data, technology, and tools to Science
37’s flourishing community provider network, we are able to support
their mission to provide access to patients who would normally not
have exposure to clinical research. With this partnership, we’ll be
able to target the more than 90% of patients in healthcare systems
who are traditionally overlooked.”
About Science 37Science 37, Inc.’s (Nasdaq:
SNCE) mission is to accelerate clinical research by enabling
universal access for patients. In 2014, we pioneered decentralized
clinical trials, and we continue to lead, delivering faster, more
inclusive, patient-centric trials, by removing barriers to access
through a tech-enabled virtual site. The Science 37 Metasite™
leverages a unified set of people, processes, and technology,
delivering greater consistency and regulatory-quality data. With
the most medical and operational experience across therapeutic
areas, Science 37 has enabled up to 21x faster enrollment, 28%
better retention, and 3x more diversity vs. the traditional site.
To learn more, visit www.science37.com, or email
science37@science37.com.
About BEKHealthBEKHealth Corporation is a
privately held, venture-backed business based in Connecticut.
BEKHealth was founded to serve a core need of clinical
research—more accurate and automated trial feasibility and patient
trial matching. By combining a proprietary AI-powered EMR
data-processing engine with easy-to-use and impactful workflow
solutions, we provide sites and CROs the ability to achieve “the
last mile” to recruit the right patients more rapidly. For more
information, visit www.bekhealth.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37, its sales pipeline and the markets in which
it operates. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) the ability to maintain
the listing of Science 37’s securities on Nasdaq, (ii) volatility
in the price of Science 37’s securities due to a variety of
factors, including changes in the competitive and highly regulated
industries in which Science 37 operates, variations in performance
across competitors, changes in laws and regulations affecting
Science 37’s business and changes in its capital structure, (iii)
the ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, (vi) failure to realize
anticipated cost savings, and (vii) the potential adverse effects
of the ongoing global COVID-19 pandemic. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of our Annual Report on Form 10-K for
the fiscal year ended December 31, 2021 filed with the U.S.
Securities and Exchange Commission (the “SEC”) on March 22, 2022
and in our other documents filed by Science 37 from time to time
with the SEC. These filings identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and Science 37 assumes no obligation
and does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as required by law. Science 37 does not give
any assurance that Science 37 will achieve its expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
Greg KalishGKC for BEKHealthgkalish@gkcomms.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024